in

The contract manufacturing market for Pharmaceuticals in China is estimated to be worth USD 13 billi

Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world

Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.”

The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features:

A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs).

A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.

A brief discussion of various regulatory guidelines in China and various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.

Detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China.

A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).

An analysis of the partnerships and acquisitions that have been established in this domain, in the recent past.

A detailed capacity analysis based on the installed reactor capacities of the manufacturing facilities in China.

A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.

  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Key Geographical Regions

Type of Product

  • Active Pharmaceutical Ingredients (APIs)
  • Drug Products

Type of Drug Product

  • Solid
  • Liquid / Semi-Solid
  • Injectable
  • Others

Scale of Operation

  • Clinical
  • Commercial

Company Size

  • Small
  • Mid-Sized
  • Large / Very Large

Key players covered in the report

2Y-Chem

Aurisco Pharmaceutical

ChemPartner

Dorrapharma

Hubei Biocause Pharmaceutical

Infoark

Ningbo Menovo Pharmaceutical

Shandong Xinhua Pharmaceutical

Shanghai Acebright Pharmaceuticals

STA Pharmaceutical

Zhejiang Huahai Pharmaceutical

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

Other Recent Offerings

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

This post was created with our nice and easy submission form. Create your post!

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Loading…

0

What do you think?

God of $DOGE: Elon Musk, Snoop Dogg, & Gene Simmons Give Big Love to DogeCoin

God of $DOGE: Elon Musk, Snoop Dogg, & Gene Simmons Give Big Love to DogeCoin

A 1,000 ETH trade via DEX aggregators can now give lower slippage than Coinbase

A 1,000 ETH trade via DEX aggregators can now give lower slippage than Coinbase